Munich Cluster for Systems Neurology

Breadcrumb Navigation


DGK and DZHK position paper on genome editing: basic science applications and future perspective

Basic Res Cardiol. 2021 Jan 15;116(1):2. doi: 10.1007/s00395-020-00839-3. PMID: 33449167.

Authors/Editors: Brandes RP, Dueck A, Engelhardt S, Kaulich M, Kupatt C, De Angelis MT, Leisegang MS, le Noble F, Moretti A, Müller OJ, Skryabin BV, Thum T, Wurst W.
Publication Date: 2021


For a long time, gene editing had been a scientific concept, which was limited to a few applications. With recent developments, following the discovery of TALEN zinc-finger endonucleases and in particular the CRISPR/Cas system, gene editing has become a technique applicable in most laboratories. The current gain- and loss-of function models in basic science are revolutionary as they allow unbiased screens of unprecedented depth and complexity and rapid development of transgenic animals. Modifications of CRISPR/Cas have been developed to precisely interrogate epigenetic regulation or to visualize DNA complexes. Moreover, gene editing as a clinical treatment option is rapidly developing with first trials on the way. This article reviews the most recent progress in the field, covering expert opinions gathered during joint conferences on genome editing of the German Cardiac Society (DGK) and the German Center for Cardiovascular Research (DZHK). Particularly focusing on the translational aspect and the combination of cellular and animal applications, the authors aim to provide direction for the development of the field and the most frequent applications with their problems.

Related Links